Immunobiology of Tomatine Adjuvant: Novel Approach to Vaccine Development

Researchers from the United States have made a significant discovery in the field of vaccine development with the review of the immunobiology of the Tomatine adjuvant in a recent issue of the journal Vaccine. According to the study, soluble or sub-unit protein vaccines alone are incapable of generating antigen-specific cellular immune responses, leading to the development of novel adjuvants that stimulate both humoral and cellular immune responses. The Tomatine adjuvant, a glycoalkaloid-based compound, has been found to stimulate potent antigen-specific humoral and cellular immune responses, contributing to protection against malaria, Francisella tularensis, and regression of experimental tumors.

Key Takeaways:

• The immunobiology of Tomatine adjuvant was reviewed in a recent issue of the journal Vaccine, highlighting its potential in vaccine development.
• Traditional sub-unit vaccines have been incapable of generating antigen-specific cellular immune responses, attributed to the manner in which the immune system processes antigen.
• Tomatine adjuvant has been found to stimulate potent antigen-specific humoral and cellular immune responses, capable of contributing to protection against malaria, Francisella tularensis, and regression of experimental tumors.
• W. John W. Morrow and colleagues at the University of Washington investigated the manner in which cellular immune responses were generated by Tomatine adjuvant using in vivo models.
• Tomatine did not require either lymph node or splenic macrophages to generate cytotoxic T lymphocytes (CTL) and delivered soluble protein into a pathway not dependent on the machinery of the classical MHC class I pathway.
• Tomatine required both CD80 and CD86 costimulation to engender antigen-specific cellular immunity at the molecular level.

Statistics:

• The study published in Vaccine was conducted by W. John W. Morrow and colleagues from the Department of Pathobiology at the University of Washington in Seattle.
• 2380-2384 (pages) in the Vaccine journal (Immunobiology of the Tomatine adjuvant. Vaccine, 2004;22(19 Sp. Iss)).
• Tomatine adjuvant was found to be effective in stimulating antigen-specific humoral and cellular immune responses against malaria, Francisella tularensis, and regression of experimental tumors.

Sources:

• Vaccine (Immunobiology of the Tomatine adjuvant. Vaccine, 2004;22(19 Sp. Iss):2380-2384).
• Malaria Weekly editors and staff, "Immunobiology of Tomatine Adjuvant: Novel Approach to Vaccine Development", NewsRx.com & NewsRx.net, 2004 SEP 6.